Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Yahoo Finance·Jun 1

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Intellia Therapeutics is set to present additional phase 3 data for its treatment lonvoguran ziclumeran, also known as lonvo-z, at the EAACI 2026 conference. The treatment has reportedly shown positive results in patients with hereditary angioedema, with some outlets indicating a significant reduction in attacks. However, there are conflicting reports on the stock's reaction to the news, with some sources stating it is down and others stating it is up.

Full coverage

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics·Jun 13

Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch Plans - What's Changed

simplywall.st·4d ago

One-time CRISPR gene edit cuts HAE attacks by 87% in Phase 3 trial

Stock Titan·Jun 13

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Intellia Therapeutics·Apr 24

CRISPR HAE therapy lonvo-z gets late-breaking EAACI 2026 slot

Stock Titan·Jun 1

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Intellia Therapeutics·Apr 27

One CRISPR dose left 62% of HAE patients attack- and therapy-free

Stock Titan·Apr 27

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Yahoo Finance·Jun 16

View original report at Yahoo Finance ↗

Fetching the latest headlines…